Works matching IS 15228517 AND DT 2022 AND VI 24 AND IP 11
Results: 27
Society News.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 2013, doi. 10.1093/neuonc/noac228
- Publication type:
- Article
Hurdling over the blood–brain barrier with exosome technology.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1884, doi. 10.1093/neuonc/noac214
- By:
- Publication type:
- Article
Improved survival among females and association with lymphopenia in patients with newly diagnosed glioblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 2005, doi. 10.1093/neuonc/noac190
- By:
- Publication type:
- Article
Erratum to: Environmental and sex-specific molecular signatures of glioma causation.
- Published in:
- 2022
- Publication type:
- Correction Notice
Corrigendum to: A preclinical model of patient-derived cerebrospinal fluid circulating tumor cells for experimental therapeutics in leptomeningeal disease from melanoma.
- Published in:
- 2022
- Publication type:
- Correction Notice
Corrigendum to: TERT promoter C228T mutation in neural progenitors confers growth advantage following telomere shortening in vivo.
- Published in:
- 2022
- Publication type:
- Correction Notice
fifth edition of the World Health Organization Classification of Tumors of the Central Nervous System: Implications for cancer registries.
- Published in:
- 2022
- By:
- Publication type:
- Editorial
Improved seizure control in patients with recurrent glioblastoma treated with bevacizumab.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 2001, doi. 10.1093/neuonc/noac172
- By:
- Publication type:
- Article
Selumetinib in children with neurofibromatosis type 1 and asymptomatic inoperable plexiform neurofibroma at risk for developing tumor-related morbidity.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1978, doi. 10.1093/neuonc/noac109
- By:
- Publication type:
- Article
BRAF inhibitors in BRAFV600E-mutated pediatric high-grade gliomas: Upfront or at recurrence?
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1976, doi. 10.1093/neuonc/noac160
- By:
- Publication type:
- Article
Targeting neddylation in cancer.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1869, doi. 10.1093/neuonc/noac159
- By:
- Publication type:
- Article
Imaging biomarkers of TERT or GABPB1 silencing in TERT-positive glioblastoma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1898, doi. 10.1093/neuonc/noac112
- By:
- Publication type:
- Article
MEK inhibitors for neurofibromatosis type 1 manifestations: Clinical evidence and consensus.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1845, doi. 10.1093/neuonc/noac165
- By:
- Publication type:
- Article
Erratum to: Cancer cell heterogeneity and plasticity: A paradigm shift in glioblastoma.
- Published in:
- 2022
- Publication type:
- Correction Notice
Management of neurofibromatosis type 1-associated plexiform neurofibromas.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1827, doi. 10.1093/neuonc/noac146
- By:
- Publication type:
- Article
Molecular biomarker-defined brain tumors: Epidemiology, validity, and completeness in the United States.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1989, doi. 10.1093/neuonc/noac113
- By:
- Publication type:
- Article
Investigational PET tracers in neuro-oncology—What's on the horizon? A report of the PET/RANO group.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1815, doi. 10.1093/neuonc/noac131
- By:
- Publication type:
- Article
CNS non-germinomatous germ cell tumor (NGGCT): Lessons from the recent past.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1962, doi. 10.1093/neuonc/noac119
- By:
- Publication type:
- Article
Phase III trial of chemoradiotherapy with temozolomide plus nivolumab or placebo for newly diagnosed glioblastoma with methylated MGMT promoter.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1935, doi. 10.1093/neuonc/noac116
- By:
- Publication type:
- Article
Factors correlating with survival following adjuvant or definitive radiosurgery for large brain metastases.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1925, doi. 10.1093/neuonc/noac106
- By:
- Publication type:
- Article
Erratum to: path-03. Ferroptosis-related long non-coding rna signatures predict prognosis in patients with glioma.
- Published in:
- 2022
- Publication type:
- Correction Notice
MEOX2 homeobox gene promotes growth of malignant gliomas.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1911, doi. 10.1093/neuonc/noac110
- By:
- Publication type:
- Article
Blood exosomes-based targeted delivery of cPLA2 siRNA and metformin to modulate glioblastoma energy metabolism for tailoring personalized therapy.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1871, doi. 10.1093/neuonc/noac071
- By:
- Publication type:
- Article
DNA methylation subclass receptor tyrosine kinase II (RTK II) is predictive for seizure development in glioblastoma patients.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1886, doi. 10.1093/neuonc/noac108
- By:
- Publication type:
- Article
Pattern of treatment failures in patients with central nervous system non-germinomatous germ cell tumors (CNS-NGGCT): A pooled analysis of clinical trials.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1950, doi. 10.1093/neuonc/noac057
- By:
- Publication type:
- Article
Upfront molecular targeted therapy for the treatment of BRAF-mutant pediatric high-grade glioma.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1964, doi. 10.1093/neuonc/noac096
- By:
- Publication type:
- Article
PTEN loss drives resistance to the neddylation inhibitor MLN4924 in glioblastoma and can be overcome with TOP2A inhibitors.
- Published in:
- Neuro-Oncology, 2022, v. 24, n. 11, p. 1857, doi. 10.1093/neuonc/noac067
- By:
- Publication type:
- Article